The National Institute of Neurological Disorders and Stroke (NINDS) requests grant applications for countermeasures against chemical threats (CounterACT) research projects. This announcement is made together with 5 other components of the National Institutes of Health (NIH).*
The increased risk of a terrorist attack in the
Areas of research interest include, but are not limited to: therapies based on acute toxicity of the chemical threat agent, e.g., development of new and/or improved anticonvulsants, neuroprotectants, new approaches to counteract pulmonary edema, relevant anti-inflammatory drugs, surfactants, or the development of better skin and eye protectants; therapies based on mechanism of action of the threat agent, e.g., reactivation/protection of acetylcholinesterase, or preservation of mitochondrial respiration; alternate formulations of existing therapeutics that possess physical and chemical characteristics that allow them to be stockpiled, e.g., longer shelf lives; improved rapid diagnostic techniques/technologies used for differential diagnosis, triage, detection of subclinical exposures, prognosis, and prediction of tissue damage; identification of biomarkers (genomic, proteomic, metabonomic) of exposure and disease progression for individual chemicals or classes of chemicals with similar signatures; and safe and effective therapies and diagnostic techniques for pediatric and elderly segments of the civilian population or for those individuals with pre-existing medical conditions.
LETTERS OF INTENT RECEIPT DATE:
APPLICATION RECEIPT DATE:
For more information, potential applicants should contact Dr. David Jett, Program Director, Technology Development Group,
NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2177, Bethesda, MD 20892; telephone:
301-496-6035; fax: 301-402-1501; e-mail: email@example.com.
*For a full list of supporting NIH components and a more detailed description of this request for applications, please visit the NIH web site at: http://grants2.nih.gov/grants/guide/rfa-files/RFA-NS-06-004.html.